Zevra Therapeutics

Yahoo Finance • 13 hours ago

Zevra Therapeutics rises amid takeover speculation

[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Z... Full story

Yahoo Finance • 8 days ago

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA off... Full story

Yahoo Finance • 22 days ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLY... Full story

Yahoo Finance • 29 days ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four p... Full story

Yahoo Finance • last month

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that m... Full story

Yahoo Finance • last month

Zevra Therapeutics gains amid takeover speculation

[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Z... Full story

Yahoo Finance • last month

Zevra Therapeutics stock price target lowered to $18 at Citizens JMP

Investing.com - Citizens JMP lowered its price target on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) to $18.00 from $19.00 on Wednesday while maintaining a Market Outperform rating. According to InvestingPro data, the stock has delivered an imp... Full story

Yahoo Finance • last month

Zevra Revenue Jumps 486 Percent in Q2

Key Points GAAP revenue rose to $25.9 million in Q2 2025, exceeding estimates by 14.8%, on strong MIPLYFFA sales and French EAP expansion. GAAP net income reached $74.7 million in Q2 2025, reversing a loss from the prior year, but was fue... Full story

Yahoo Finance • last month

Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet

Earnings Call Insights: Zevra Therapeutics (ZVRA) Q2 2025 MANAGEMENT VIEW * Neil F. McFarlane, President and CEO, highlighted that "Q2 net revenue reached $25.9 million, reflecting robust demand and effective operational execution." He... Full story

Yahoo Finance • last month

Earnings call transcript: Zevra Therapeutics Q2 2025 misses EPS, revenue shines

Zevra Therapeutics reported its Q2 2025 earnings, revealing a mixed financial performance. The company posted an earnings per share (EPS) of -$0.06, significantly missing the forecasted $2.19. However, revenue came in at $25.9 million, sur... Full story

Yahoo Finance • last month

Zevra Therapeutics, Inc. Non-GAAP EPS of -$0.06 misses by $1.44, revenue of $25.88M beats by $3.39M

* Zevra Therapeutics, Inc. press release [https://seekingalpha.com/pr/20198646-zevra-reports-second-quarter-2025-financial-results-and-corporate-update] (NASDAQ:ZVRA [https://seekingalpha.com/symbol/ZVRA]): Q2 Non-GAAP EPS of -$0.06 miss... Full story

Yahoo Finance • last month

Zevra Therapeutics Q2 2025 Earnings Preview

* Zevra Therapeutics (NASDAQ:ZVRA [https://seekingalpha.com/symbol/ZVRA]) is scheduled to announce Q2 earnings results on Tuesday, August 12th, after market close. * The consensus EPS Estimate is $1.38 [https://seekingalpha.com/symbol/... Full story

Yahoo Finance • 2 months ago

Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

CELEBRATION, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that m... Full story

Yahoo Finance • 2 months ago

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it wil... Full story

Yahoo Finance • 2 months ago

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company... Full story

Yahoo Finance • 3 months ago

Tesla, Circle Internet Surge Among Monday's Market Cap Stock Movers

Monday’s trading session is showcasing significant movements across various market cap categories. Mega-cap giants like Tesla Motors (NASDAQ:TSLA) and Palantir Technologies Inc (NASDAQ:PLTR) have experienced notable shifts, while large... Full story

Yahoo Finance • 3 months ago

Zevra Therapeutics' SWOT analysis: strong MIPLYFFA launch boosts stock outlook

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been making waves in the pharmaceutical industry with its successful launch of MIPLYFFA, a treatment for Niemann-Pick Disease Type C (NPC). The company’s strategic focus on rare diseases and stron... Full story

Yahoo Finance • 4 months ago

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

In a report released on May 27, Jason Butler from Citizens JMP reiterated a Buy rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) with a price target of $19.00. Its fiscal Q1 2025 results, reported on May 15, showed positive operations, wi... Full story

Yahoo Finance • last year

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease Friday, the FDA approved  Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Miplyffa (arimoclomol), an oral medication for Neimann-Pick disease,... Full story

Yahoo Finance • 2 years ago

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics on track to close Q4 2023 and will diversify Zevra’s revenue with FDA-approved OLPRUVA® for urea cycle disorders (UCDs) Net re... Full story